跳转至内容
Merck
所有图片(2)

主要文件

查看所有文档

S9318

Sigma-Aldrich

Sandoz 58-035

>98% (HPLC), powder, acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor

别名:

3-[癸基二甲基甲硅烷基] -N- [2-（4-甲基苯基）-1-苯乙基]丙酰胺, SA 58-035

登录查看公司和协议定价
所有图片(2)

About This Item

经验公式（希尔记法）:
C30H47NOSi
CAS号:
78934-83-5
分子量:
465.79
MDL號碼:
MFCD00161339
分類程式碼代碼:
41121801
PubChem物質ID:
24278227
NACRES:
NA.77

产品名称

Sandoz 58-035, >98% (HPLC), powder

品質等級

100

化驗

>98% (HPLC)

形狀

powder

顏色

white

溶解度

DMSO: 16 mg/mL
H2O: insoluble

起源

Novartis

儲存溫度

2-8°C

SMILES 字串

CCCCCCCCCC[Si](C)(C)CCC(=O)NC(Cc1ccc(C)cc1)c2ccccc2

InChI

1S/C30H47NOSi/c1-5-6-7-8-9-10-11-15-23-33(3,4)24-22-30(32)31-29(28-16-13-12-14-17-28)25-27-20-18-26(2)19-21-27/h12-14,16-21,29H,5-11,15,22-25H2,1-4H3,(H,31,32)

InChI 密鑰

NBYATBIMYLFITE-UHFFFAOYSA-N

基因資訊

human ... SOAT1(6646)
rat ... Soat1(81782)

應用

Sandoz 58-035 用于诱导小鼠腹腔巨噬细胞中未折叠蛋白反应（UPR）和模式识别受体（PRR）的同时激活。3

生化／生理作用

Sandoz 58-035 抑制胆固醇酯的积累，抑制培养物中动脉平滑肌细胞 95％ 的胆固醇酯化。1它不影响肠道甘油三酯代谢。2
酰基辅酶 A：胆固醇酰基转移酶（ACAT）抑制剂。

特點和優勢

该化合物由 Novartis 开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
0000283252
0000283252
0000179274
065M4602V
122M4604V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Masato Furuhashi et al.
Scientific reports, 7(1), 217-217 (2017-03-18)
Cholesterol efflux capacity (CEC) from macrophages, the first step in the reverse cholesterol transport pathway, is inversely associated with residual risk for atherosclerotic cardiovascular disease. Fatty acid-binding protein 4 (FABP4) and FABP5 are expressed in both adipocytes and macrophages and
Julia T Stadler et al.
Biomedicines, 9(3) (2021-03-07)
Obesity increases the risk of coronary heart disease, partly due to its strong association with atherogenic dyslipidemia, characterized by high triglycerides and low high-density lipoprotein (HDL) cholesterol levels. Functional impairment of HDL may contribute to the increased cardiovascular mortality, but
Markus Trieb et al.
Journal of hepatology, 73(1), 113-120 (2020-02-18)
High-density lipoprotein cholesterol (HDL-C) levels are reduced in patients with chronic liver disease and inversely correlate with disease severity. During acute conditions such as sepsis, HDL-C levels decrease rapidly and HDL particles undergo profound changes in their composition and function.
Irene Schilcher et al.
Scientific reports, 7(1), 12485-12485 (2017-10-04)
Endothelial lipase (EL) is a potent modulator of the structural and functional properties of HDL. Impact of EL on cholesterol efflux capacity (CEC) of serum and isolated HDL is not well understood and apparently contradictory data were published. Here, we
Shizuya Yamashita et al.
Journal of clinical lipidology, 12(5), 1267-1279 (2018-08-06)
Cardiovascular risk is negatively correlated with cholesterol efflux capacity (CEC) from macrophages to high-density lipoproteins (HDLs) and positively correlated with fasting and nonfasting triglyceride-rich lipoproteins (TRLs). Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator, robustly decreases the fasting TRL
查看所有相关文献

商品

Cholesterol Esterification

Cholesterol esterification enhances transport efficiency in lipoproteins for increased blood stream transport.

Cholesterol Esterification

Cholesterol esterification enhances transport efficiency in lipoproteins for increased blood stream transport.

Cholesterol Esterification

Cholesterol esterification enhances transport efficiency in lipoproteins for increased blood stream transport.

Cholesterol Esterification

Cholesterol esterification enhances transport efficiency in lipoproteins for increased blood stream transport.

查看所有结果

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门